GlassScriptPhysician profile
Samuel J King
NPI 1235314998
$1,281.76
in general payments reported to CMS, 2019-2025
22 companies · $379 in 2025
The $379 reported for 2025 was more than what 89% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $128 · 2021: $74.19 · 2022: $102 · 2023: $146 · 2024: $169 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $215.87 | 2019-2025 | |
| Lilly USA, LLC | $129.58 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $125.66 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $124.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $112.13 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $107.30 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $91.97 | 2019 | |
| Calliditas Therapeutics US INC. | $58.69 | 2025 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.21 | 2020-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.65 | 2019 | |
| Eisai INC. | $28.49 | 2024 | |
| Tonix Medicines, INC. | $25.61 | 2025 | Tonmya |
| Allergan, INC. | $23.46 | 2020 | |
| Mallinckrodt Hospital Products INC. | $22.22 | 2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $19.67 | 2023 | Gattex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $18.23 | 2025 | |
| Tris Pharma INC | $17.81 | 2024 | Dyanavel Xr |
| Abbvie INC. | $17.43 | 2023 | |
| Halozyme INC | $14.87 | 2023 | |
| Eagle Pharmaceuticals, INC. | $14.52 | 2023 | |
| Acacia Pharma INC | $14.27 | 2021 | |
| Medtronic USA, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.